MDxHealth's Q3 revenue misses expectations due to disrupted commercial execution

Overview

• Precision diagnostics firm's Q3 revenue was flat yr/yr, missing analyst expectations

• Net loss widened 26% yr/yr, driven by higher operating expenses from ExoDx acquisition

• Company cites sales team turnover and commercial restructuring as factors impacting Q3 results

Outlook

• Company expects to exit Q4 with a fully staffed and trained sales organization

• MDxHealth aims to return to growth in 2027 following commercial restructuring

• Company plans to roll out strategic AI initiatives in first half of 2027

Result Drivers

• SALES TEAM TURNOVER - Accelerated turnover in its sales organization disrupted commercial execution in Q3

• OPERATING LOSS - Increased 86% compared to the prior year, due to increased operating expenses related to ExoDx acquisition in September 2025

• TEST MIX IMPACT - Gross margin declined due to a lower proportion of tissue-based tests in revenue mix

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for MDxHealth SA is $1.00, about 582.6% above its November 11 closing price of $0.15

Reuters Recommended Reads

• Nov 12 - Lucid Diagnostics Q3 revenue misses analyst expectations

• Nov 10 - Belgium's Agfa-Gevaert Q3 revenue flat, adjusted EBITDA drops on volume declines

• Nov 9 - Coherus Oncology Q3 sales miss estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)